Building Bridges!

As part of the Hamburg cluster bridging initiative, the cluster organizations Life Science Nord Management GmbH and Gesundheitswirtschaft Hamburg GmbH are jointly working on two projects that cover the topics hygiene, infection, health and eHealth under a coordinated strategy.

Funding

The HIHeal project is financed by the European Fund for Regional Development (EFRE) and the City of Hamburg. The project will receive funding for a five-year period (April 1, 2016 to March 31, 2021).
Dear Readers,

Globalization and climate change facilitate the rapid spread in infections. Emerging diseases such as Ebola, EHEC and MERS as well as hospital infections represent a particular challenge to the life science sector.

In addition, bacterial infectious agents are becoming increasingly resistant to antibiotics throughout the world, with profound economic and health implications. The World Health Organization (WHO) now describes antibiotic-resistant bacteria as “a serious threat to medical progress”.

Besides the creation of an efficient research structure to understand infection mechanisms, two approaches are key to tackling these problems. First, improved hygiene measures to contain infections and their spread, second and the restrictive use of antibiotics to prevent resistance.

The innovation network HIHeal (Hygiene, Infection & Health) was launched in 2016 and adressses this important issues by linking companies, scientific institutions, hospitals and funding bodies in Northern Germany. The project, which will run for five years, is funded by the European Fund for Regional Development (EFRE) and the city of Hamburg. Its main focus is on prevention, diagnostics, acute therapies and areas of clinical innovation. The goals include generating synergies by strengthening networks among experts and combining their expertise, promoting cooperation and initiating innovative projects.

In this network guide, we present the regional partners in the HiHeal Network and their areas of competence.

If you wish to find out more about HIHeal, please let us know.

Dr. Hinrich Habeck
Managing Director

Dr. Friederike Saathoff
Network Coordinator HIHeal
Life Science Nord is the regional network for medical technology, biotechnology and pharma in Hamburg und Schleswig-Holstein. About 500 companies are located in the region. In 2014, they generated gross value added of € 4.0 billion. Some 42,300 employees work in the industrial health economy in Northern Germany.*

The business landscape and valuation creation in the life sciences

The business landscape in the North is broadly based and includes both large groups and many small and mid-sized businesses. The latter represent the backbone of the economy – SMEs generate about 70% of gross value added*. A further notable feature of the cluster is the existence of a complete value chain in the region: from basic and applied research to clinical trials and the final marketable product. The region thus has one of the most extensive clusters of the industrial health industry in Europe. In addition, there is a diverse research landscape in Hamburg and Schleswig-Holstein – besides the university medical centers (Hamburg-Eppendorf (UKE), Schleswig-Holstein (UKSH)) numerous renowned research institutes such as DESY, the Research Center Borstel, the Heinrich-Pette Institute for Experimental Virology and the Bernhard-Nocht Institute for Tropical Medicine are located in the region.

The network as an innovation engine

The life sciences are a dynamic sector in Northern Germany in which new products and solutions are regularly developed. In Northern Germany, there are traditional established areas of expertise in which innovations are developed. In medical technology, the focus is mainly on imaging technologies, precision surgery and implantology. Companies in the biotechnology and pharmaceuticals sectors concentrate above all on drug research, molecular diagnostics, platform technologies as well as laboratory equipment and supplies.

Networking among the sector players forms an important basis for the region’s innovative strength. Moreover, the cluster helps bring together the interests and needs of the sector to promote and develop the region further.

Cluster Management and the Association

In 2004, Hamburg and Schleswig-Holstein decided to provide targeted support to the life science industry in Northern Germany by establishing Life Science Nord, a cluster management agency that operates across both states. Since then, the cluster has been known as Life Science Nord. Moreover, about 240 companies are organized in the similarly named Life Science Nord e.V. (up to 2013 Bay to Bio e.V.), a registered association that represents the interests of the sector. The association and the Management GmbH work together to promote life sciences in the region and create one of the leading life science clusters in Europe. As the central point of contact for the sector, Life Science Nord Management also initiates and advises on international and regional projects that sharpen the region’s profile.
4,0 bn gross value added of the cluster in 2014

SMALL AND MEDIUM-sized enterprises with up to 249 EMPLOYEES are the cluster’s main economic pillar

42,300 persons in employment in the cluster in 2014

More than 7 OUT OF 10 PERSONS employed in the Life Science Nord cluster work in small and medium-sized enterprises (SME).

5,8 bn cluster’s exports in 2014

* According to WifOR study 2016
HIHEAL
THE NORTH’S NETWORK FOR HYGIENE AND INFECTION

Have you or your company been working on an innovative idea for some time? Or is there a project that requires partners, funding or other structures? Are you considering a new approach that represents an absolute value added when it comes to tackling and preventing infections?

Through HIHeal, the regional innovation cluster, we can support you

→ by systematically pooling and providing expertise in infectious diseases in Northern Germany
→ by helping you find cooperation partners on a regional, national and international level to initiate new joint projects
→ in arranging events, conferences and working groups in the region
→ in defining new infection-relevant areas of focus in Northern Germany
Particular areas of focus:

• Prevention  
• Diagnostics  
• Acute therapies  
• Clinical fields of innovation

Advisory board

The network is supported by a group of local business, hospital and political experts. The following players are members of the advisory board for the project and assist the HIHeal innovation cluster with their expertise:

• Ministry of Health and Consumer Protection Free and Hanseatic City of Hamburg  
• Ministry of Science, Research and Equalities Free and Hanseatic City of Hamburg  
• Ministry of Economy, Transport and Innovation Free and Hanseatic City of Hamburg  
• University Medical Center Hamburg-Eppendorf (UKE)  
• Olympus Surgical Technologies Europe  
• Dr. Brill + Partner GmbH Institute for Hygiene and Microbiology  
• altona Diagnostics GmbH  
• Bode Chemie GmbH
ALTONA DIAGNOSTICS GMBH

COMPANY PROFILE

About altona Diagnostics GmbH

altona Diagnostics, founded 2007 in Hamburg, Germany, is focused on the development, manufacturing and marketing of molecular diagnostic test systems for the detection and quantification of pathogens in the field of infectious diseases.

The founders and staff of altona Diagnostics have a broad experience in molecular diagnostics and corresponding technologies.

The fully integrated diagnostic company is offering a broad range of complete, CE-IVD marked real-time PCR kits. altona Diagnostics especially focuses on emerging pathogens.

As one of the first companies altona Diagnostics made reliable molecular diagnostic kits commercially available during outbreak situations for SARS, avian Flu, swine Flu, EHEC, MERS, Ebolavirus and Zika virus. altona Diagnostics is ISO 13485 certified.
ANCHOR DIAGNOSTICS GMBH

COMPANY PROFILE

Anchor Diagnostics GmbH aims to contribute to the advancement of today’s molecular diagnostic landscape by improving the combination of clinical diagnostics and therapy.

The company is dedicated to the development of solutions enabling the immediate initiation of patient treatment by supporting a speedy, innovative and reliable verification of pathogenic patterns. As the ultimate goal customers should be permitted to perform real “near patient“-testing also outside the classical diagnostic environments.

The team behind Anchor Diagnostics is having extensive experience in developing products for in vitro diagnostic use and is working for more than 15 years in the area of molecular diagnostics. The track record does include the responsibility for the design and development of more than 30 CE-IVD certified kits gaining a couple of international product registrations, including FDA-approvals.

Current products are intended for use within the field of central laboratory testing to accelerate throughput, time-to-result and the overall workflow management. These Real-Time-PCR-based diagnostic kits provide significantly reduced lead times. The particularly developed assay chemistry allows the application of different technical platforms.

Although not necessarily limited to, product development activities are focused on infectious disease-related targets.

Anchor Diagnostics is offering its expertise to interested parties and is very open for collaborations to further strengthen its network. Anchor Diagnostics is ISO 13485 certified, also for contract development and production.
BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE (BNITM)

COMPANY PROFILE

BNITM is Germany’s largest institution for research, services and training in the field of tropical diseases and emerging infections. Research topics include clinical studies, epidemiology and disease control as well as the biology of the respective pathogens, their reservoirs and vectors. The current scientific focus is on malaria, haemorrhagic fever viruses, tissue nematodes and diagnostics development. To study highly pathogenic viruses and infected insects, the institute is equipped with laboratories of the highest biosafety level (BSL4) and a BSL3 insectary. Outstanding scientific achievements include scientific work concerning the Ebola outbreak in West Africa.

Services of the institute include specific laboratory diagnostics of tropical diseases, emerging and other rare infections, a close co-operation with the German army as well as consultation of the scientific community, industry, politics and the public, which greatly contribute to the national standing of the institute. The institute comprises the National Reference Centre for Tropical Pathogens and the WHO Collaborating Centre for Arbovirus and Haemorrhagic Fever Reference and Research.

Teaching activities include a 3-months, full-time course on all aspects of tropical medicine for physicians, a structured training programme for PhD students and a number of activities of continuing education in topics related to travel medicine and international health.

In co-operation with the Ghanaian Ministry of Health and Kwame Nkrumah University of Science and Technology in Kumasi, the institute since more than ten years runs the Kumasi Centre for Collaborative Research in Tropical Medicine (KCCR), a modern research and training centre in Ghana, which is also available to external research groups.

As a member of the Leibniz Association and a research institute of national importance, the institute is jointly funded by the Federal Government, the Free and Hanseatic City of Hamburg and the other federal states.
CAMPTON DIAGNOSTICS UG

COMPANY PROFILE

CAMPTON Diagnostics, a Spin-Off company from the Fraunhofer Institute for Silicon Technology (ISIT), develops rapid and sensitive analysis systems for the Point-of-Care diagnostics. The portable analysis device, the CAMPTON Biochip Reader offers a rapid test result, which would therefore be advantageous in the field of medical care. The mobile system provides many advantages for customers as well as doctors and hospitals, because it makes cheaper and more time efficient on-site diagnostics available. It takes less than 15 minutes to do the test and get the results immediately. Out of a small drop of whole blood collected by the biochip cartridge, the system allows the detection of different biomarkers to identify corresponding diseases.
FRAUNHOFER INSTITUTE FOR SILICON TECHNOLOGY (ISIT)

COMPANY PROFILE

Fraunhofer ISIT in Itzehoe is one of Europe's most modern research facilities for microelectronics and microsystems technology. The heart of the institute are the cleanroom facilities, big enough to operate not only research projects but also to produce the developed microchips in industrial scale. 190 scientists develop at ISIT in close cooperation with industrial partners power electronic components and microsystems, with fine movable structures for sensors (pressure, movement, biochemical analysis, etc.) and actuators (valves, scanners, micromirrors etc.) including the necessary electronics. These miniaturized components are used in medicine, in the environment - and traffic engineering, communication technology, automotive industry and mechanical engineering.

The biosensor technology team develops and produces silicon based microsystems for high sophisticated biosensors used in miniaturized and mobile analysis platforms. The research focus addresses especially the topic “microsystems for health”.

CONTACT

Dr. Eric Nebling
Fraunhoferstrasse 1
25524 Itzehoe

PHONE: +49 4821 / 174312
FAX: +49 4821 / 174250

eric.nebling@isit.fraunhofer.de
www.isit.fraunhofer.de

NUMBER OF EMPLOYEES: 190
FOUNDING YEAR: 1995
RESEARCH CENTER BORSTEL, LEIBNIZ LUNG CENTER

COMPANY PROFILE

In addition to the research laboratories, the "Research Center Borstel, Leibniz Lung Center" operates a medical clinic with a connected pathology and medical care center, as well as the National Reference Center for Mycobacteria.

The Center treats chronic inflammatory lung diseases. The focus is on non-infection-related diseases such as asthma and allergies as well as the chronic obstructive pulmonary disease (COPD). On the other hand, inflammation of the lungs, especially tuberculosis, is caused by infection. The overall aim of the fundamentally interdisciplinary research activities is to elucidate the causes and mechanisms of chronic inflammatory and degenerative diseases of the lungs in order to derive new innovative concepts for their diagnosis, prevention and therapy.

The research area (RA) ‘Infections’ deals with infectious-inflammatory lung diseases with a particular focus on tuberculosis (TB). The RA combines studies on the genomic diversity of the TB pathogens, the evolution and spread of various pathogen variants, their virulence and persistence, and analyzes the genetic and physiological basis of the pathobiological properties being responsible for the susceptibility of the host or its protection against the infection or the disease. Special attention is paid to further improve the diagnosis and clinical management of patients with resistant TB, as well as to monitor the spread of multiple-resistant strains by effective molecular-epidemiological monitoring of the pathogens. High-throughput sequencing are used for the genome analysis of clinical tuberculosis strains and is combined with complex studies on host response to infection at the immunological and metabolic levels. Thus offering new possibilities for targeted antibiotic development as well as target structures for innovative host-modulating therapies, so-called host-directed therapies (HDT).
KSK DIAGNOSTICS GMBH

COMPANY PROFILE

KSK Diagnostics GmbH is focused on the development, production and marketing of test systems based on its unique isothermal amplification technology allowing the rapid diagnostic of infectious diseases, antibiotic resistances and tumor markers.

KSK Diagnostics GmbH has developed KDx rITA®, a novel isothermal amplification technology. Key benefit of this technology is the reduction of run time from sample to result to less than 30 minutes. This enables precise therapeutic decisions in a new dimension beyond medical laboratories and time consuming sample logistics. Only a minimal instrumental effort is needed to run the test. The tests can be executed by trained medical staff near patient’s site. High specificity and sensitivity will be achieved through amplification on high and constant temperature. Sensitivity and specificity are at least on the level of Real-Time PCR systems but KDx rITA® is less sensitive to inhibitory substances. The amplification and analysis takes only 15 minutes. Isothermal amplification makes it possible to use simple and robust instruments. However, also standard Real-Time PCR cyclers already existing in diagnostic laboratories can be used.

Using KDx rITA tests multiple targets can be analyzed in one tube. The high level multiplexing is an enormous advantage in contrast to other isothermal procedures.

KSK Diagnostics GmbH has its headquarters in Hamburg. Its founders Dr. Stefan Kulick, Dr. Peter Scheinert and Dr. Guido Krupp are an experienced management team with a successful track record. Innovationsstarter Fonds Hamburg and High-Tech Gründerfonds are among the company’s investors.
M-U-T GMBH

COMPANY PROFILE

QSP can detect bacteria and toxins - qualitatively as well as quantitatively, very fast and with a low detection threshold.

Base of QSP (QSP=Quantitative highest sensitive Particle Measurement) is an extremely sensitive particle detector which works like a light barrier on molecular level. It determines quantity and size of particles (20 nm down to 5 µm) in a sample. The theoretical threshold is 10 fg/l. In combination with magnetic nano-particles which we coat with anti-bodies we are able to create tests like a sandwich ELISA test on a molecular level with test results within minutes. There are many application possibilities for the QSP technology in hygienic topics from a simple smear-test for a hygienic control of surfaces to a MRSA screening device to protect your employees and your patients. QSP is the answer to a lot of challenges.

m-u-t GmbH is part of the m-u-t group. m-u-t group is a turn-key provider for efficient solutions in photonics. Contact-free optical measurement technology can optimize a large variety of strongly growing future markets in a resource-efficient and environmentally friendly manner. m-u-t GmbH offers more than 20 years of expertise in optical measurement technology in a large range: from UV and VIS via NIR and MIR to LWIR. m-u-t GmbH develops and produces systems for use in medical and life science applications, industrial environments, in train systems as well as in agriculture and environmental technology. Systems are developed customer-specific – from idea stage all the way to series product. m-u-t GmbH develops, produces and services serial products for OEM customers.

We are specialized on application-specific solutions of measurement tasks. You are the expert on your application; we contribute technology- and realization competence. We produce the products according to highest quality standards and manage the whole life cycle for you.
MEDILYS LABORGESELLSCHAFT MBH

COMPANY PROFILE

The MEDILYS Laborgesellschaft is a subsidiary medical laboratory company of the Asklepios chain of hospitals with its main diagnostic activities centered in and around Hamburg. MEDILYS serves the hospitals of the Asklepios Kliniken Hamburg GmbH, as well as hospitals in northern Germany and other medical facilities. The MEDILYS Laborgesellschaft mbH provides a wide range of laboratory diagnostics as well as hospital hygiene and microbiological examinations, among others a supervision of the Drinking Water Ordinance.

Each year we analyse over 15 million samples in the field of clinical chemistry, haematology, haemostaseology, serology and molecular genetics. We also carry out over 440,000 bacterial diagnostic tests. A particular focus of our company, among other things, is on hospital hygiene.

This includes the certified monitoring of the drinking water supply. Our main emphasis is the prevention of infections in the clinical field and the management of antibiotic stewardship.

The interdisciplinary cooperation with the department of microbiology particularly promotes the rapid diagnostics of bacterial and viral pathogens and tests their sensitivity to antibiotics. This process allows competent advice on specific strategies to treat severe infections.
OLYMPUS SURGICAL TECHNOLOGIES EUROPE

COMPANY PROFILE

As a worldwide leading manufacturer of optical and digital precision technology, Olympus provides innovative solutions for state-of-the-art medical systems, digital cameras and scientific solutions. The company’s award-winning products are instrumental in detecting, preventing and healing illness, driving scientific research and documenting life with artistic freedom. In the hands of its customers, Olympus’ high-tech products help to make people’s lives healthier, safer and more fulfilling.

As high-tech specialist within the Olympus Corporation, Olympus Surgical Technologies Europe is the development and manufacturing center for endoscopy, bipolar high-frequency surgery, systems integration in operating rooms and instrument reprocessing systems. With a total workforce of 1,700 employees in Hamburg and further locations in Teltow (Berlin), Přerov (Czech Republic) and Cardiff (Wales) the company stands for outstanding performance in medical diagnostic and therapy and offers the full range of most modern endoscopy applications from single products to procedure oriented systems solutions.
UNIVERSITY MEDICAL CENTER HAMBURG-EPPENDORF (UKE)

COMPANY PROFILE

Since its foundation in 1889, the Medical Center Hamburg-Eppendorf has been one of the leading clinics in Europe. Here specialists from all fields of medicine are brought together under one roof. State-of-the-art medical technology, innovative information technology, and architecture created with the provision of medical care at the forefront, all with the aim of optimally supporting doctors, nursing staff, and therapists. The ideal conditions for the interlinkage between modern medicine, research, and teaching are found at the UKE. More than 10,000 employees work around the clock with the singular aim of providing the best medical care to our patients.

About 2,600 of the employees are medical specialists and researchers, while more than 3,200 work as nurses and therapists. Together with its University Heart Center Hamburg and the Martini Clinic, the UKE has more than 1,720 beds.

Research is an important prerequisite for progress in diagnostics and therapy. The emphasis in UKE’s research are the neurosciences, cardiovascular research, care research, oncology, as well as infections and inflammations. Other potential areas of the UKE are molecular imaging and skeletal biology research.

The UKE educates about 3,800 medical specialists and dentists. Some of our students achieve significantly better than average results in performance tests in Germany. We are praised throughout the country for our modern training techniques in which theory and practice are interconnected in an exceptional and progressive manner, and in which topical elements such as digital textbooks or computer-based simulation programs are utilized. The model study course iMED Hamburg, which was introduced in 2012, already fulfills the criteria for the further development of medical studies in Germany which were defined by the Science Council.
UNIVERSITY HOSPITAL SCHLESWIG-HOLSTEIN (UKSH)

COMPANY PROFILE

The University Hospital Schleswig-Holstein (UKSH) with its locations in Kiel and Lübeck is one of the largest medical centers in Europe. The key feature of the university medicine is the interplay of health care, research and teaching with the effect that scientific findings are directly incorporated into the patient’s health care (translation). Together with the Dean’s Office of the Christian-Albrechts-University of Kiel and the Senate Committee of the University of Lübeck, the UKSH meets the challenges of medicine in the 21st century.

The UKSH, as the only maximum care provider of the northernmost state, provides individualized diagnostics and therapy for 500,000 people that is every 6th inhabitant as well as providing a quarter of all hospital services in the area. The 85 clinics and institutes have the full spectrum of modern medicine, especially for patients who need a highly differentiated medicine and an emergency care around the clock. The average severity of the cases is a third higher than in other main hospitals of the area.

The UKSH generates a total assets of approx. 1.2 billion euros, and plays a major role in health care as the largest employer with 13,000 employees from 120 nations and as well as an important training company.
ASTRAZENECA GMBH

COMPANY PROFILE

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas – Respiratory, Inflammation & Autoimmunity, Cardiovascular & Metabolic diseases, and Oncology – as well as in Infection and Neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Our three strategic R&D sites are located close to globally recognised bioscience clusters, making it easier to access world-class talent and opportunities for collaboration and partnerships.

AstraZeneca Germany is among the largest research-based pharmaceutical companies in Germany. Our company headquarters are located in Wedel in Schleswig-Holstein.
BRANDENBURG ANTIINFECTIVA GMBH

COMPANY PROFILE

Brandenburg Antiinfektiva GmbH provides a platform technology for the development of newly designed synthetic peptides for treatment of systemic and non-systemic, bacterial and viral diseases, with a focus on sepsis. Despite improvement in medical care, severe sepsis and septic shock remain an unmet medical need. In addition, the increase in resistance of bacteria represents a massive threat of health supply. Aspidasept®, our lead development candidate efficiently neutralizes the fatal effects of bacterial infections and administration of their toxins with unprecedented results in animal models. The drug is in late preclinical development stages for the treatment of sepsis, but also for severe SSTI (skin- and soft tissue infections).

Our approach: • Design and development of novel toxin-neutralizing polypeptides, originally based on the lipid A-part of LPS. • Mode of action: High affinity binding to bacterial toxins, suppressing inflammation-induction by these compounds in immune cells. • Preclinical development of the polypeptides, with a focus on our primary development candidate Aspidasept®, in vitro, ex vivo and in vivo. • Proof of concept and tolerance shown in animal models. • Proof of antibacterial activity against multiresistant germs (MRSA and others). • Proof of antiviral activity against Herpes Simplex I and II, hepatitis B, human papillomavirus, HIV, influenza (flu) serotypes H3N2 and H1N1, and swine fever. • Aspidasept® development status: Late preclinical phase.

CTC NORTH GMBH & CO. KG

COMPANY PROFILE

CLINICAL TRIAL CENTER NORTH (CTC North) is a CRO located at the University Medical Center Hamburg-Eppendorf. Its objective is to guarantee the professional conduct of clinical trials in accordance with ICH-GCP, the German Drug Law (AMG) and the German Medical Device Law (MPG) within a university environment. Since 2006 CTC North has been providing a comprehensive range of professional services for clinical Phase I-IV trials at the University Medical Center Hamburg-Eppendorf.

**General Services** Complete clinical trial management for UKE researchers as well as for the Pharmaceutical, Biotech and Medtech Industry • Support services for clinicians managing European Research Grant applications • Professional recruitment services (patients, healthy and special populations) • Monitoring • Data Management and Biostatistics • Medical Writing • Quality Management • Advisory and consulting services for all aspects of clinical development and conduct • Professional training courses for investigators and study nurses (GCP, German Drug Law, Medical Device Law).

**Phase I Services** Planning, clinical conduct and analysis of Phase I trials from first-in-man up to proof-of-concept providing a link between healthy volunteer and early patient trials • Full Phase I trial setting with a highly experienced core team and state-of-the-art facilities and equipment.

**Phase II-IV Services** Multicenter study management and monitoring • Clinical conduct of Phase II to IV trials in a professional university setting • Close collaboration with clinical and research specialists at the UKE and other institutions in the Hamburg area • A large pool of highly experienced research nurses.
EVOTEC AG

COMPANY PROFILE

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. Drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and consulting arrangements. The Company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. By leveraging this expertise, Evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased and comprehensive infrastructure.

Evotec has long-term discovery alliances with partners including Bayer, CHDI, Sanofi, Genentech, Janssen Pharmaceuticals and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships e.g. with e.g. Janssen Pharmaceuticals in the field of Alzheimer’s disease, with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and with Celgene in the field of neurodegenerative diseases.

Evotec is built on integrated drug discovery know-how of over 20 years and is a leading player in the drug discovery field. The Company’s headquarters are located in Hamburg, Germany. Additional major operating sites exist in Abingdon and Manchester, UK; Göttingen and Munich, Germany, Bradford, Princeton, Watertown and USA as well as Toulouse, France, Verona, Italy and Basel, Switzerland. Evotec has more than 2,000 employees worldwide.
HEINRICH PETTE INSTITUTE, LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY

COMPANY PROFILE

The Heinrich Pette Institute, Leibniz Institute for Experimental Virology (HPI) investigates the biology of human pathogenic viruses with the aim of unraveling the molecular mechanisms that control viral life cycles and virus induced pathogenesis. The institute applies basic experimental research to develop new approaches for contemporary treatments of viral infections such as AIDS, influenza and hepatitis but also of emerging viral diseases.

The HPI was established by the philanthropist Philipp F. Reemtsma and the neurologist Heinrich Pette in 1948. The institute is a non-profit, independent research foundation that is part of the Leibniz Association.
PENTAX MEDICAL

COMPANY PROFILE

PENTAX Medical is a division of HOYA Group. Its mission is to improve the standard of patient care and quality of healthcare delivery by providing the best endoscopic products and services with a focus on quality, clinically relevant innovations and simplicity. Through leading edge R&D and manufacturing, PENTAX Medical provides endoscopic imaging devices and solutions to the global medical community. PENTAX Medical has a worldwide focus and presence with R&D, regional sales, service, and in-country facilities around the globe.

For more information, please visit: www.pentaxmedical.com.
PREVENTION
AQUA FREE GMBH

COMPANY PROFILE

Waterborne germs such as Pseudomonas and Legionella in drinking water pipework can be dangerous. Special attention is necessary to protect vulnerable people from infection.

Aqua free is devoted to the task of maintaining and improving water hygiene. Founded in Hamburg in 1999, the company started life as a manufacturer of sterile water filters for healthcare application. Today Aqua free is a certified medical device company and not only develops and produces high quality water filters and other products but also provides a comprehensive range of services all focused on water hygiene.

Our portfolio of medical water hygiene products includes sterile water filters for a wide variety of medical applications - both point-of-use and in-line systems - and also offers bespoke system solutions. Our Service team, who are all trained in operating in high risk medical environments, support clients in facing the everyday challenges presented by water hygiene. Hospitals and medical practices trust Aqua free products and services to provide permanent protection for their patients and employees.

The quality of our medical products, and the skill and knowledge behind them is reflected in our range of Legionella and bacteria water filters designed to suit domestic, commercial and industrial clients. Our filters and other technical hygiene products provide immediate protection from germs in drinking water for a wide range of applications such as households, hotels, public buildings, factories, mobile homes.

Some problems are very specific and require individual solutions. Aqua free has a history of working closely with clients from industry and commerce to develop bespoke filtration solutions to suit specific applications and guidelines. Aqua free is recognised as a specialist water hygiene partner throughout Europe.
CONTACT

Dr. Heide Niesalla  
Melanchthonstraße 27  
22525 Hamburg  

PHONE: +49 40 / 54006 287  
FAX: +49 40 / 54006 777  
heide.niesalla@bode-chemie.de  
www.bode-science-center.com  

NUMBER OF EMPLOYEES: 350  
FOUNDING YEAR: 1924

BODE CHEMIE GMBH

COMPANY PROFILE

Since 2009, BODE has been a wholly owned subsidiary of PAUL HARTMANN AG in Heidenheim, Germany. With the acquisition, both companies have been able to expand their expertise in infection protection.

Aiming at offering our customers scientifically proven solutions, the BODE SCIENCE CENTER was established in 2011, as scientific center of excellence of the HARTMANN GROUP, combining science and practice in infection protection.

The BODE SCIENCE CENTER conducts research on current issues of infection prevention and develops practical solutions for patient protection. To improve patient protection, it systematically puts emphasis on making infection control knowledge and measures available and improve them in daily routine with a focus on practical solutions. The scientific center of excellence conducts own research projects: on improving compliance, optimized working processes and much more. For this, it closely co-operates with partners from clinical practice.

The center’s comprehensive web portal - www.bode-science-center.com - provides well-founded information on infection protection from an extensive range of information and suggestions such as pathogen search, hygiene management for differing infectious diseases to informative articles on hand and surface hygiene.
DR. BRILL + PARTNER GMBH
INSTITUT FÜR HYGIENE
UND MIKROBIOLOGIE

COMPANY PROFILE

Dr. Brill + Partner GmbH Institut für Hygiene und Mikrobiologie is a leading service provider with regard to applied hygiene, microbiology and virology in Europe. The services of the German-based family company include consulting, training and laboratory services. More than 50 experts provide their expertise in the fields of service of disinfectants, cosmetics, medical devices, pharmaceutical products, water and bio corrosion as well as human and veterinary hygiene.

The Dr. Brill Group serves its international customers from three different locations. The laboratories that are accredited according to EN ISO / IEC 17025 and recognized by the ZLG are located in Hamburg and Bremen. In 2014, our first foreign subsidiary was founded in Dubai, United Arab Emirates, to strengthen our international presence.

We provide support during the development, registration and launch of products as well as in the scientific marketing with specialized lectures and publications. In addition, we consult and train in the field of hygiene within the healthcare, industry and microbial material degradation and material protection.

The strong scientific focus with our more than 20 scientists enables us to closely cooperate with partners and clients all over the world. Our goal is to understand our clients’ needs in detail in order to provide tailor-made services. This strategy is in our hearts and minds. As a family company we are interested in long-term successful relationships.
CENTRE FOR STRUCTURAL SYSTEMS BIOLOGY

COMPANY PROFILE

A lack of knowledge of the molecular mechanisms underlying most infections presents a roadblock to the development of effective therapies. Molecular, structural and functional analysis, which uncovers and manipulates infection mechanisms, is essential for ensuring a rapid and effective response to current and future epidemics. The Centre for Structural Systems Biology (CSSB) is primarily focused on uncovering the molecular properties and ingenuities of infection mechanisms. CSSB advocates a novel approach which integrates the use of structural biology and imaging techniques with systems biology methods to attain meaningful insight into the molecular mechanisms of some of the world’s most important infections.

To conduct its structural biology research, CSSB uses the world-renowned X-ray light sources in Hamburg: the synchrotron storage ring, PETRA III, and the free electron laser, European XFEL. The beamlines of these facilities will be used in conjunction with cryo electron microscopy and a range of “omics” technologies, available at CSSB, to provide a full range of structural biology and analytical techniques. With this unique combination of research methods and tools, CSSB endeavours to investigate a wide range of interactions involved in the infection process: from the molecular level of interactions to single cells, viral and bacterial pathogens, and ultimately entire host organisms.

CSSB is joint initiative of ten research partners from Northern Germany including three universities and seven research institutes – three Helmholtz Centres, three Leibniz Institutes and the European Molecular Biology Laboratory.

CSSB is a cooperation without its own legal personality. All partners act exclusively in their own name and on their own account.
CHEMISCHE FABRIK DR. WEIGERT GMBH & CO. KG

COMPANY PROFILE

Taking responsibility with inspiring results
Systematic hygiene – that is our company slogan, which perfectly captures the essence of our business: we successfully ensure hygiene in many sectors, industries and countries. Safety and trust are particular priorities for us here. After all, Dr. Weigert has been impressing its customers with 100% reliability and professionalism from the outset. This applies to our products and system solutions as well as every single one of our employees. Our long-standing business relationships with our customers, partners and suppliers show that we at Dr. Weigert impress with our commitment – at the same time, this is an incentive for us to constantly set new standards. Our employees impress through performance, efficiency and individuality.

Extensive and individual advice on all aspects of cleaning and disinfection give our customers maximum safety and value for money in product application and when planning hygiene measures. At our locations, efficient and transparent corporate structures combined with the expertise of our committed employees ensure outstanding results. Quality, growth and flexibility ensure lasting success.

At Dr. Weigert, growth is a matter of quality before quantity. Values such as dedication, continuity and soundness are closely linked with this principle. Our unique expertise and wide range of skills in automated and manual cleaning and disinfection are the result of a company history stretching back more than 100 years.

The enduring success of Dr. Weigert is based on market-oriented, forward-looking product development, innovations and individual solutions. Our safe logistics solutions and supplying our customers quickly and flexibly are key parts of the Dr. Weigert success concept.
NANDATEC GMBH

COMPANY PROFILE

nandatec® GmbH is a Nanobiotechnology company focusing on biochemical engineering and surface modification of biocompatible nanoparticles for applications in the fields of Life Sciences, particularly in Regenerative Medicine, Medical Technology, Biosensing and Clean Tech.

We provide a variety of services ranging from product development, clinical studies in a GMP-, AMG-, MPG-certified clinical trial center to bioinformatical analysis.

If you have any questions concerning our products or services, please feel free to contact us.

For further information please visit https://www.nandatec.com.
PC FRESH

COMPANY PROFILE

The PC fresh system makes it possible to reduce the pathogens on and in computers, notebooks, keyboards and other IT equipment by 99.999% (a 5 log reduction). This has been confirmed by functional testing and by tests carried out at the HYGCEN Germany accredited testing laboratory. The new cleaning and sterilisation process was developed with support from Germany’s Ministry for Economic Affairs and Technology as part of its SME patent campaign.

PC fresh combines mechanical compressed-air technology with physical irradiation disinfection in a single mobile service station. First of all dust particles are removed in the cleaning chamber. Then the devices are disinfected inside and out in the sterilisation chamber using UV-C radiation - no chemicals, no air contamination, no noise. The whole process takes about 15 minutes and is carried out on site in the medical setting. That means system cleaning and disinfection can be integrated into any IT maintenance routine.

Large amounts of dust particles and microorganisms collect in computers. Sucked in by ventilation fans they form thick layers of fluff and dirt that constitute a risk for people and IT systems. Dirt and fluff on system components reduces cooling, permits current leakage and can lead to malfunctioning and system breakdowns. The pathogens harboured by the dirt represent an even greater threat. Examination of swap samples has shown levels of >100 pathogens on about 25 square centimeters. Furthermore, pathogens able to withstand dryness can be released by the circulation of dust and spores. IT equipment in medical settings can thus become a dangerous source of pathogens which increase the risk of infection – not only for patients with compromised immune systems but also for staff members.

The PC fresh cleaning process effectively deactivates this hidden risk for people and technology and is thus a useful new component in a comprehensive hygiene plan.
SCHÜLKE & MAYR GMBH

COMPANY PROFILE

Germs know no bounds. This has held true since time immemorial and, in our present globalised world, is of steadily growing importance. However, the risks that germs pose to humans and materials are regularly underestimated. In order to combat these risks effectively, optimum hygiene conditions are among the major requirements for success. schülke has set itself the task of closing this hygiene gap: within the context of a holistic approach. Disinfectants, antiseptics, preservatives, biocides, medical skin care products, active ingredients for deodorants and system cleaners form the main focus of the range of products we develop and produce. Together with expert advice, specific training and first-class service, our customers can avail themselves of comprehensive, individual hygiene solutions. Our claim is both guideline and yardstick. The quality of a whole hygiene chain is equal only to that of each link within that chain. That is why we are uncompromising in our holistic approach. In this way, we create more than economic success: sustained value for the environment and society.

schülke is driving its transformation from a tradition-steeped chemical enterprise to a modern partner for the pharmaceutical and chemical industries. Since 1996, we have been a 100 % subsidiary of the Air Liquide Group, world leader in gases, technologies and services for industry and health. With 21 international subsidiaries and a presence in 100 countries, we generate an annual turnover of roughly 322 million Euro. Our headquarters in Norderstedt near Hamburg are the focal point of all our activities. Here, all of our central divisions work hand in hand: from Research and Development, Management, Production and Marketing, to Sales and Logistics. As one of the market leaders in infection control, we provide major impetus from here: for our continuous global growth – and for successful hygiene solutions for our customers.
UNIVERSITÄT HAMBURG, FACULTY FOR MATHEMATICS, INFORMATICS AND NATURAL SCIENCES

COMPANY PROFILE

The Universität Hamburg is the largest research and educational institution in northern Germany. As one of the country’s largest universities, we offer a diverse range of taught programs coupled with excellent research. In addition to climate, earth and environment, our key research areas are photon and nanosciences, manuscript cultures, neurosciences, infection research / structural systems biology, particle physics, astrophysics and mathematical physics, and health economics.

The Faculty of Mathematics, Informatics and Natural Sciences (MIN) comprises the Departments of Biology, Chemistry, Earth Science, Informatics, Mathematics, and Physics. Around 8,500 students, of which 1,000 are doctoral students and 1,800 trainee teachers, are taught and supervised by some 200 professors and 370 postdoctoral research assistants.

In recent years, the MIN Faculty has earned an outstanding reputation for research and teaching. One key research area is "Infection Research and Structural Systems Biology".

The research done at the University Medical Center Hamburg-Eppendorf (UKE) focuses particularly on human and organ-based infections as well as molecular infection biology in the mammalian model. The MIN Faculty, especially chemistry and biology, focus their research on human infections, antibiotics, but also on different animal and plant systems as well as on a wide spectrum of host and germs and their general mechanisms. In the future infection control will be a big research topic.

Since 2012 Universität Hamburg and UKE form in collaboration with other universities and research institutions one of seven sites of the German Center for Infection Research (DZIF). At the newly opened Center for Structural Systems Biology (CSSB) scientists from ten different research institutions are investigating infections interdisciplinary.
HELIOS ENDO-KLINIK HAMBURG

COMPANY PROFILE

Helios ENDO-Klinik Hamburg has become one of the leading specialist medical centres worldwide over the last couple of decades. The Helios ENDO-Klinik is a specialized clinic for bone, joint, and spinal surgery which has achieved a worldwide reputation due to its outstanding competence in the treatment of diseases of the support and locomotor system.

During the last 41 years more than 7,800 patients per year have placed their trust in medical knowledge and excellently qualified staff, who make this clinic a center of special competence.

Surgeons of the ENDO-Klinik have implanted more than 155,000 joint replacements since the foundation in 1976. With the specialists for neurosurgery, the Helios ENDO-Klinik has a high competence of treating diseases of the spinal column and the surrounding nerves. Other specialist services include sports orthopaedics and physiotherapy. There is an ENDO rehab centre on Campus.

Helios ENDO-Klinik features 5 departments, 203 beds, and 128 rooms. The rooms are well-designed to provide patients with comfort. The clinic offers the high-quality services for its patients and makes their stay very comfortable, too.

The Helios ENDO-Klinik is especially specialized in:
• Joint surgery for hip, knee, shoulder, ankle or elbow joints – arthroscopy, endoprosthetics and surface replacement, corrections and reconstructions
• Joint surgery for septic cases/infections – revision interventions
• Spinal surgery – intervertebral prolapses, stenoses or degenerative changes of the spine – corrections, stabilisations, fusions, decompressions
• Neurosurgery – interventions of the spinal cord, tumor operations of the osseous spine as well as spinal membranes, spinal nerves and the spinal cord and sports orthopaedics
## REGISTER A – Z

<table>
<thead>
<tr>
<th>Company</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A</strong></td>
<td></td>
</tr>
<tr>
<td>Altona Diagnostics GmbH</td>
<td>12</td>
</tr>
<tr>
<td>Anchor Diagnostics GmbH</td>
<td>13</td>
</tr>
<tr>
<td>Aqua Free GmbH</td>
<td>34</td>
</tr>
<tr>
<td>Astrazeneca GmbH</td>
<td>26</td>
</tr>
<tr>
<td><strong>B</strong></td>
<td></td>
</tr>
<tr>
<td>Bernhard Nocht Institute For Tropical Medicine (BNITM)</td>
<td>14</td>
</tr>
<tr>
<td>Bode Chemie GmbH</td>
<td>35</td>
</tr>
<tr>
<td>Brandenburg Antiinfektiva GmbH</td>
<td>27</td>
</tr>
<tr>
<td><strong>C</strong></td>
<td></td>
</tr>
<tr>
<td>Campton Diagnostics UG</td>
<td>15</td>
</tr>
<tr>
<td>Centre for Structural Systems Biology</td>
<td>37</td>
</tr>
<tr>
<td>Chemische Fabrik Dr. Weigert GmbH &amp; Co. KG</td>
<td>38</td>
</tr>
<tr>
<td>CTC North GmbH &amp; Co. KG</td>
<td>28</td>
</tr>
<tr>
<td><strong>D</strong></td>
<td></td>
</tr>
<tr>
<td>Dr. Brill + Partner GmbH Institut Für Hygiene und Mikrobiologie</td>
<td>36</td>
</tr>
<tr>
<td><strong>E</strong></td>
<td></td>
</tr>
<tr>
<td>Evotec AG</td>
<td>29</td>
</tr>
<tr>
<td><strong>F</strong></td>
<td></td>
</tr>
<tr>
<td>Fraunhofer Institute for Silicon Technology (ISIT)</td>
<td>16</td>
</tr>
<tr>
<td><strong>H</strong></td>
<td></td>
</tr>
<tr>
<td>Heinrich Pette Institute, Leibniz Institute for Experimental Virology</td>
<td>30</td>
</tr>
<tr>
<td>Helios Endo-Klinik Hamburg</td>
<td>43</td>
</tr>
<tr>
<td><strong>K</strong></td>
<td></td>
</tr>
<tr>
<td>KSK Diagnostics GmbH</td>
<td>18</td>
</tr>
<tr>
<td>Company</td>
<td>Page</td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>Medilys Laborgesellschaft MbH</td>
<td>20</td>
</tr>
<tr>
<td>m-u-t GmbH</td>
<td>19</td>
</tr>
<tr>
<td>Nandatec GmbH</td>
<td>39</td>
</tr>
<tr>
<td>Olympus Surgical Technologies Europe</td>
<td>21</td>
</tr>
<tr>
<td>PC Fresh GmbH</td>
<td>40</td>
</tr>
<tr>
<td>Pentax Medical GmbH</td>
<td>31</td>
</tr>
<tr>
<td>Research Center Borstel, Leibniz Lung Center</td>
<td>17</td>
</tr>
<tr>
<td>Schülke &amp; Mayr GmbH</td>
<td>41</td>
</tr>
<tr>
<td>Universität Hamburg, Faculty for Mathematics, Informatics and Natural Sciences</td>
<td>42</td>
</tr>
<tr>
<td>University Hospital Schleswig-Holstein (UKSH)</td>
<td>23</td>
</tr>
<tr>
<td>University Medical Center Hamburg-Eppendorf (UKE)</td>
<td>22</td>
</tr>
</tbody>
</table>
Bb-Antiinfektiva